Versions Compared

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.

In this study, subjects were randomized to different flavors doses of a nicotine lozengesinhaler. The recommended usage instruction for the lozenge nicotine inhaler were provided to the subject at each visit.  At visit 1-3 subjects were to use 1 lozenges 6-10 cartridges per day every 2 hours, and during visit 4-6 subjects were to use 1 lozenge every 4- 8 hours.  3-6 cartridges per day. Subject were encouraged to not to use any other tobacco products, nicotine replacement therapies  therapies or alcohol during the study. Data on usage of these products were collected using an e-diary, where the subject provided information on the product used each day.   Only days were a product was used  used were represented. 

Alcohol usage and tobacco product usage were represented in the SU domain. SUCAT allows the records to be grouped into tobacco -related data and alcohol related data.   In this example, the products prespecified so SUTRT does not require a standardized SUDECOD equivalent. The sponsor only include SUSTDTC and SUENDTC as timing variables.   

Dataset wrap
Rowcaps
Row 1 Shows the cigarettes used for the day of assessment. SUDOSFRQ was represented using the controlled terminology for per day, QD.   
Rows 2-3 Show 2 other records for a subject's usage of tobacco products on two other days.   
Row 4 Shows the subjects use of alcohol. Note, the sponsor collected the ounces of the product used using a  pre-specified amount per drink. 
Dataset2
RowSTUDYIDDOMAINUSUBJIDSUSEQSUTRTSUCATSUDOSESUDOSU

SUDOSFR

SUSTDTCSUENDTC
1TLXS111SUABC-010011CIGARETTETOBACCO1CIGARETTE

QD


2020-06-262020-06-26
2TLXS111SUABC-010012CIGARTOBACCO2CIGARQD2020-07-272020-07-27
3TLXS111SUABC-010013CIGARETTETOBACCO1CIGARETTEQD2020-08-152020-07-15
4TLXS111SUABC-020011BEERALOCHOL ALCOHOL 24OZQD2021-09-152021-09-15

Drugs used in nicotine dependency are  considered  are considered medically acceptable drugs and were represented in the Concomitant Medication (CM) domain. This subject used a 14 mg nicotine replacement patch . The sponsor included the CMCLA, CMDECOD, and CM MODIFY. These were included to reflect standardized coding of the medication.  

Dataset wrap
NameCM
Dataset2
RowSTUDYIDDOMAINUSUBJIDCMSEQCMTRTCMMODIFYCMCLASCMDOSECMDECODCMDOSU

CMDOSFRM

CMSTDTCCMENDTC
1TLXS111SUCMABC-010071Nicotine Replacement Patch  Nicotine DRUGS USED IN  NICOTINE DEPENDENCE14Nicotinemg

PATCH


2020-06-262020-06-26

A Product Accountability (DA) domain was used to record the amount of study product transferred to or from the study subjects. At each visit the subject was supplied with 2 bottles of lozenges that contained 40 lozenges each,  The number of lozenges  returned 90 cartridges per week for weeks 1-3, and 50 cartridges per week for weeks 4-6. The number of cartridge returned were counted. DACAT was used to indicate that the products of interest was the study product.  DDASPID and DAREFID can be used for code numbers that appeared on the study product label, in this case no code numbers were used on the labels. The sponsor included VISITNUM and DADTC as these variables are expected in this domain. DADTC was the date the supplies were dispensed or  or returned, these corresponded to the dates of the visits.   

Dataset wrap
NameDA
Rowcaps
Rows 1,3  Show the dispensed amount of lozenges number of cartridges dispensed to the subject. In this example, the total number of lozenges dispensed were tracked, and not the bottles.    
Rows 2 4 Shows the amount number of lozenges cartridges returned by the subject. 
LOZENGE
Dataset2
RowSTUDYIDDOMAINUSUBJIDDASEQDATESTDACAT
DASCAT
DAORRESDAORRESUDASTRESCDASTRESNDASTRESUVISITNUMDADTC
1TLXS111DAABC-01001

1

Dispensed AmountSTUDY PRODUCT
LOZENGE
90
80
CARTRIDGE
LOZENGE
60
80
60
80
CARTRIDGE12004-06-26
2TLXS111DAABC-01001
3

2

Returned AmountSTUDY PRODUCT
LOZENGE
13
24
CARTRIDGE
LOZENGE
2424
LOZENGE
CARTRIDGE22020-07-06
3TLXS111DAABC-01001
5

3

Dispensed AmountSTUDY PRODUCT
LOZENGE
90
80LOZENGE
CARTRIDGE8080
LOZENGE
CARTRIDGE22020-07-06
4TLXS111DAABC-01001
7

4

Returned AmountSTUDY PRODUCT
LOZENGE
10
34LOZENGE
CARTRIDGE3434
LOZENGE
CARTRIDGE32020-07-14

The sponsor the recommended usage instruction for the lozenge were provided to the subject at each visit. At visit 1-3 subjects were to use 1 lozenges 6 -10 cartridges per day every 2 hours, and during visit 4-6 subjects used 1 lozenge every 4- 8 hours. The were to use 3-6 cartridges per day.  The sponsor used the EC domain to represent the collected exposure data.   These usage recommendations were represented in DOSRGM, which is the intended Dose Regimen.    

The ECMOOD  permissible; variable was used to reflect the intended usage recommendations and the actual usage of the lozengesinhaled nicotine. When this variable is used, it must be populated for all records. This variable can not be used in EX.  

Dataset wrap
Nameec
Rowcaps
Row 1    Show the scheduled usage recommendation for the lozengeinhaled nicotine.  Note, the details on the scheduled records are described at a different  level than the performed records. ECDOSRGM shows that for these start and end dates the subject was recommended to use the lozenges every 1- 2 hours6-12 cartridges every day.   
Rows 2, 3 Shows the actual "performed" amount of lozenges inhaled nicotine used by the subject each day. Note only a few rows of the performed records are shown.    
Row 4   Show the scheduled usage recommendation for the lozengeinhaled nicotine ECDOSRGM ECDOSRGM shows that for these start and end dates the subject was recommended to use 1  lozenges every 4-8  hours3-6 cartridges  per day..    
Row 5Shows the actual "performed" amount of inhaled nicotine used by the subject each day. Note only a few rows of the performed records are shown.    
Dataset2
RowSTUDYIDDOMAINUSUBJIDECSEQECTRTECMOODECDOSECDOSUECDOSFREQECDOSRGM ECROUTEEPOCHECSTDTCECENDTC
1TLXS111ECTLX7011Nicotine Lozenge  SCHEDULEDLozengeCARTRIDGEEvery 1-2 hours
 6 -10 cartridges per dayRESPIRATORY (INHALATION)ORAL TREATMENT2004-06-262004-7-31
2TLXS111ECTLX7012Nicotine Lozenge  PERFORMED7LozengeCARTRIDGEQDORAL
IRESPIRATORY (INHALATION)TREATMENT2004-06-262004-06-26
3TLXS111ECTLX7013Nicotine Lozenge  PERFORMED2LozengeCARTRIDGE

IRESPIRATORY (INHALATION)ORALTREATMENT2004-06-272004-06-27
4TLXS111ECTLX2001TLX7014Nicotine Lozenge  SCHEDULED1 LozengeCARTRIDGEEvery 4-8 hours
3-6 cartridges per dayRESPIRATORY (INHALATION)L ORAL TREATMENT2004-08-202004-09-14
5TLXS111ECTLX1001TLX7015Nicotine Lozenge  PERFORMED3LozengeCARTRIDGEQDORAL
RESPIRATORY (INHALATION)TREATMENT2004-08-202004-08-20

The EX dataset shows the actual administrations. Note  Note the scheduled records are not included. Only a few rows are shown for illustration. The pharmaceutical strength was included to identify what dose of the nicotine inhaler was used by the subject   

Dataset wrap
Nameex

  

Dataset2
RowSTUDYIDDOMAINUSUBJIDEXSEQEXTRTEXDOSEEXDOSUEXDOSFRQEXROUTEECPSTRGECPSTRGUEPOCHEXSTDTCEXENDTC
1ABCEXABC10011Lozenge Cherry Flavor    7INHALED NICOTINE   13CARTRIDGELOZENGEQDRESPIRATORY (INHALATION)6mgORAL TREATMENT2004-06-262004-06-26
2ABCEXABC20012Lozenge Cherry Flavor    INHALED NICOTINE   5LOZENGECARTRIDGEQDRESPIRATORY (INHALATION)6mgORAL TREATMENT2011-06-272011-06-27
3ABCEXABC20021Lozenge Mint Flavor    INHALED NICOTINE     6LOZENGECARTRIDGEQDRESPIRATORY (INHALATION)4mgORALTREATMENT2011-08-282011-08-28
4ABCEXABC20022Lozenge Mint Flavor  INHALED NICOTINE  17LOZENGECARTRIDGEQDRESPIRATORY (INHALATION)4mgORALTREATMENT2011-08-292011-08-29